Anifrolumab

Monoclonal antibody

Approvedregulatory verdict

Evidence outlook

Approved: Systemic Lupus Erythematosus

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also in development:Idiopathic Inflammatory Myopathies · Phase 3 · investigational in the USSystemic Sclerosis · Phase 3 · investigational in the US

Also approved (2)
EU
  • Saphnelo is indicated as an add-on therapy for the treatment of adult patients with moderate to severe, active autoantibody-positive systemic lupus erythematosus (SLE), despite standard therapy.
Product first approved 2022EMA
JP
  • Saphnelo: adult patients with systemic lupus erythematosus
Product first approved 2021astrazeneca.com

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (13)
Idiopathic Inflammatory Myopathies
Systemic Lupus Erythematosus
NCT07691970 · AstraZeneca
2026-08-31 – 2032-12-30 · Systemic Sclerosis Cutaneous Lupus E Myopathies Systemic Lupus Erythematosus
What this study did
NCT05835310 · AstraZeneca
2024-03-14 – 2030-01-09 · Systemic Lupus Erythematosus
What this study did
NCT07430306 · AstraZeneca
2026-04-13 – 2029-01-26 · Systemic Lupus Erythematosus
What this study did
NCT05138133 · AstraZeneca
2022-02-15 – 2028-10-04 · Lupus Nephritis
What this study did
NCT07751848 · AstraZeneca
2026-08-31 – 2028-08-30 · Lupus Erythematosus, Systemic
What this study did
NCT02794285 · AstraZeneca
2016-06-30 – 2021-12-21 · Active Systemic Lupus Erythematosus
What this study did
Systemic Sclerosis
NCT05925803 · AstraZeneca
2023-11-08 – 2028-04-05 · Systemic Sclerosis, Scleroderma
What this study did
Other / comorbidity
NCT06015737 · AstraZeneca
2024-06-29 – 2027-08-10 · Cutaneous Lupus Erythematosus
What this study did
Phase 2 (12)
Systemic Lupus Erythematosus
NCT05440422 · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
2023-12-07 – 2027-08-02 · Systemic Lupus Erythematosus, Cardiovascular Disease, Premature Atherosclerosis
What this study did
NCT02547922 · AstraZeneca
2015-11-04 – 2021-01-18 · Lupus Nephritis
What this study did
NCT01753193 · MedImmune LLC
2013-03-28 – 2018-07-18 · Lupus Erythematosus, Systemic
What this study did
NCT01559090 · AstraZeneca
2012-04-20 – 2017-02-21 · Systemic Lupus Erythematosus
What this study did
Other / comorbidity
NCT07584083 · National and Kapodistrian University of Athens
2026-04-29 – 2028-06 · Antiphospholipid Syndrome (APS)
What this study did
NCT06374212 · University of North Carolina, Chapel Hill
2024-06-21 – 2026-07-15 · Hidradenitis Suppurativa, Acne Inversa, Hidradenitis
What this study did
NCT05917561 · University Hospital, Bordeaux
2023-12-15 – 2026-05-01 · Vitiligo
What this study did
NCT05383677 · University Medical Center Groningen
2022-10-01 – 2024-08-01 · Sjogren's Syndrome
What this study did
NCT03435601 · Josef Smolen, Univ. Prof. Dr.
2018-04-18 – 2021-03 · Rheumatoid Arthritis
What this study did
Phase 1 (7)
Systemic Lupus Erythematosus
NCT07688980 · AstraZeneca
2026-10-30 – 2030-06-14 · Systemic Lupus Erythematosus
What this study did
NCT04726553 · Oklahoma Medical Research Foundation
2021-01-20 – 2024-12-31 · Systemic Lupus Erythematosus (SLE)
What this study did
NCT05001698 · AstraZeneca
2021-07-27 – 2022-06-02 · Systemic Lupus Erythematosus
What this study did
Other / comorbidity
NCT06662123 · AstraZeneca
2024-10-21 – 2025-01-10 · Healthy Volunteers
What this study did
NCT05339100 · AstraZeneca
2022-03-22 – 2023-04-13 · Healthy Participants Study
What this study did
NCT02601625 · AstraZeneca
2015-11-16 – 2016-05-25 · Safety, Pharmacokinetics, Healthy Subjects
What this study did
NCT00930683 · MedImmune LLC
2009-09 – 2011-07 · Scleroderma
What this study did
Phase 4 (2)
Systemic Lupus Erythematosus
NCT07611214 · Aurinia Pharmaceuticals Inc.
2026-04-22 – 2029-03-02 · Lupus Nephritis
What this study did
NCT06594068 · AstraZeneca
2026-01-16 – 2027-08-31 · Systemic Lupus Erythematosus
What this study did
Early phase / not applicable (1)
Systemic Lupus Erythematosus
NCT07913919 · University of Cambridge
2025-11-28 – 2027-11-01 · Systemic Lupus Erythematosus, Atherosclerosis Generalized
What this study did

Competitive landscape

This drug's own stage for Idiopathic Inflammatory Myopathies: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Anifrolumab: this drugPhase 3Monoclonal antibodyType I interferon receptor subunit 1 (IFNAR1)not yet gradedNo reviewed efficacy summary in this indication
Brepocitinib (Lisraya)ApprovedSmall moleculeTYK2/JAK1not yet gradedNo reviewed efficacy summary in this indication
Repository Corticotropin (Acthar Gel)ApprovedPeptideMelanocortin receptors (primarily MC2R on the adrenal cortex), Melanocortin 2 receptor (MC2R) (agonist)not yet gradedNo reviewed efficacy summary in this indication
XmAb657Phase 1Multispecific antibodyCD19 x CD3not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(14 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Anifrolumab to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (5)
January 2027 (1)
Phase 3Systemic SclerosisActive not recruiting
Est. primary completion 2027-01-06 · NCT05925803 · CT.gov ↗
What to watch
February 2027 (1)
Phase 3Systemic Lupus ErythematosusActive not recruiting
Est. primary completion 2027-02-23 · NCT05138133 · CT.gov ↗
What to watch
August 2027 (2)
Phase 2Systemic Lupus ErythematosusRecruiting
Est. primary completion 2027-08-01 · NCT05440422 · CT.gov ↗
What to watch
Phase 4Systemic Lupus ErythematosusRecruiting
Est. primary completion 2027-08-31 · NCT06594068 · CT.gov ↗
What to watch
September 2027 (1)
Early phase / not applicableSystemic Lupus ErythematosusRecruiting
Est. primary completion 2027-09-01 · NCT07913919 · CT.gov ↗
What to watch
2028 (4)
January 2028 (1)
Phase 3Idiopathic Inflammatory MyopathiesRecruiting
Est. primary completion 2028-01-10 · NCT06455449 · CT.gov ↗
What to watch
June 2028 (1)
Phase 2Antiphospholipid Syndrome (APS)Recruiting
Est. primary completion 2028-06 · NCT07584083 · CT.gov ↗
What to watch
August 2028 (1)
Phase 3Systemic Lupus ErythematosusRecruiting
Est. primary completion 2028-08-25 · NCT07751848 · CT.gov ↗
What to watch
October 2028 (1)
Phase 3Systemic Lupus ErythematosusRecruiting
Est. primary completion 2028-10-05 · NCT05835310 · CT.gov ↗
What to watch
2029 (3)
January 2029 (1)
Phase 3Systemic Lupus ErythematosusRecruiting
Est. primary completion 2029-01-26 · NCT07430306 · CT.gov ↗
What to watch
March 2029 (1)
Phase 4Systemic Lupus ErythematosusRecruiting
Est. primary completion 2029-03-02 · NCT07611214 · CT.gov ↗
What to watch
April 2029 (1)
Phase 1Systemic Lupus ErythematosusNot yet recruiting
Est. primary completion 2029-04-13 · NCT07688980 · CT.gov ↗
What to watch
2030 (1)
September 2030 (1)
Phase 2Systemic Lupus ErythematosusRecruiting
Est. primary completion 2030-09-02 · NCT07630714 · CT.gov ↗
What to watch
2032 (1)
December 2032 (1)
Phase 3Systemic Lupus ErythematosusRecruiting
Est. primary completion 2032-12-30 · NCT07691970 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

17 September 2025Topline resultPhase III TULIP-SC of subcutaneous anifrolumab met its primary endpoint
AstraZeneca · Source ↗